Professor John Crown was awarded the DCU President’s Impact Award for research he leads at the National Institute for Cellular Biotechnology (NICB) to improve the treatment options available to women with metastatic HER2-positive breast cancer. Under his leadership, a new drug combination to treat women with this type of breast cancer, that is based on prior preclinical studies from the Cancer Clinical Research Trust (CCRT) research team based in the NICB, has entered clinical development in a recently opened Phase 1 clinical trial named CAROLINE-1. The CAROLINE-1 study received support from CCRT, The Caroline Foundation, BreastPredict and Puma Biotechnology Inc.
Similar Posts
Celebrating the Knockaville Cake Sale
Huge thanks goes to Marcella Bell and the The Knockaville Cake Sale Committee who have had…
CCRT Trial Process Mapping and Away Day
Optimising clinical trials is paramount for delivering effective treatments to our patients. The UCD Cancer Trials…
Professor John Crown launches a podcast “Second Opinions, with John Crown”
We are delighted to announce that Professor John Crown has recently launched a podcast interviewing stalwarts…
Golf Classic in Loving Memory of Corina Staunton
There was great support for this year’s golf classic in loving memory of Corina Staunton. In…
Kildare Place National School, Endurance Swim Fundraiser
We are so proud of the Kildare Place National School Swim Squad, in Rathmines, who undertook…
First-in-world, Caroline-1 clinical trial, will commence this month at St. Vincent’s University Hospital under the leadership of Professor John Crown
As a result of many years of collaborative research by CCRT and The Caroline Foundation funded researchers based…